SG10201607976WA - Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl Fumarate - Google Patents
Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl FumarateInfo
- Publication number
- SG10201607976WA SG10201607976WA SG10201607976WA SG10201607976WA SG10201607976WA SG 10201607976W A SG10201607976W A SG 10201607976WA SG 10201607976W A SG10201607976W A SG 10201607976WA SG 10201607976W A SG10201607976W A SG 10201607976WA SG 10201607976W A SG10201607976W A SG 10201607976WA
- Authority
- SG
- Singapore
- Prior art keywords
- laquinimod
- treatment
- combination
- multiple sclerosis
- dimethyl fumarate
- Prior art date
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title 1
- 229960004419 dimethyl fumarate Drugs 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Exchange Systems With Centralized Control (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616337P | 2012-03-27 | 2012-03-27 | |
| US13/800,047 US20130259856A1 (en) | 2012-03-27 | 2013-03-13 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201607976WA true SG10201607976WA (en) | 2016-11-29 |
Family
ID=49235339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607976WA SG10201607976WA (en) | 2012-03-27 | 2013-03-26 | Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl Fumarate |
| SG11201405755QA SG11201405755QA (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405755QA SG11201405755QA (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20130259856A1 (enExample) |
| EP (1) | EP2830623A4 (enExample) |
| JP (2) | JP2015512406A (enExample) |
| KR (1) | KR20150003765A (enExample) |
| CN (2) | CN105853422A (enExample) |
| AR (1) | AR090491A1 (enExample) |
| AU (2) | AU2013239850A1 (enExample) |
| CA (1) | CA2868259A1 (enExample) |
| EA (1) | EA201491773A1 (enExample) |
| HK (1) | HK1205941A1 (enExample) |
| IL (1) | IL234687A0 (enExample) |
| MX (1) | MX2014011616A (enExample) |
| SG (2) | SG10201607976WA (enExample) |
| TW (1) | TW201343164A (enExample) |
| UY (1) | UY34720A (enExample) |
| WO (1) | WO2013148690A1 (enExample) |
| ZA (1) | ZA201407722B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140056973A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| US9233927B2 (en) | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| CA2939990C (en) | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| WO2016091996A1 (en) | 2014-12-11 | 2016-06-16 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| US12483171B2 (en) | 2023-12-18 | 2025-11-25 | Abb Schweiz Ag | Plug and play solid state controller for high efficiency motors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2007006308A1 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| US7989473B2 (en) * | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
| ES2916604T1 (es) * | 2007-02-08 | 2022-07-04 | Biogen Ma Inc | Ensayos de detección de nrf2 y métodos y composiciones relacionados |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| CA2760133A1 (en) * | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
| DK2442651T3 (en) * | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| SI2533634T1 (sl) | 2010-02-12 | 2016-01-29 | Biogen Ma Inc. | Nevroprotekcija pri demielinizacijskih boleznih |
| JP2014510557A (ja) * | 2011-01-25 | 2014-05-01 | ノバルティス アーゲー | 動作の撮像および取込みを医療で使用するためのシステムおよび方法 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
-
2013
- 2013-03-13 US US13/800,047 patent/US20130259856A1/en not_active Abandoned
- 2013-03-25 AR ARP130100966 patent/AR090491A1/es unknown
- 2013-03-25 TW TW102110549A patent/TW201343164A/zh unknown
- 2013-03-26 AU AU2013239850A patent/AU2013239850A1/en not_active Abandoned
- 2013-03-26 EP EP13768294.4A patent/EP2830623A4/en not_active Withdrawn
- 2013-03-26 CA CA 2868259 patent/CA2868259A1/en not_active Abandoned
- 2013-03-26 MX MX2014011616A patent/MX2014011616A/es unknown
- 2013-03-26 CN CN201610252021.1A patent/CN105853422A/zh active Pending
- 2013-03-26 HK HK15106555.7A patent/HK1205941A1/xx unknown
- 2013-03-26 EA EA201491773A patent/EA201491773A1/ru unknown
- 2013-03-26 CN CN201380016933.3A patent/CN104470520A/zh active Pending
- 2013-03-26 SG SG10201607976WA patent/SG10201607976WA/en unknown
- 2013-03-26 KR KR20147030064A patent/KR20150003765A/ko not_active Withdrawn
- 2013-03-26 JP JP2015503465A patent/JP2015512406A/ja not_active Withdrawn
- 2013-03-26 WO PCT/US2013/033885 patent/WO2013148690A1/en not_active Ceased
- 2013-03-26 SG SG11201405755QA patent/SG11201405755QA/en unknown
- 2013-04-02 UY UY34720A patent/UY34720A/es not_active Application Discontinuation
-
2014
- 2014-09-16 IL IL234687A patent/IL234687A0/en unknown
- 2014-10-23 ZA ZA2014/07722A patent/ZA201407722B/en unknown
-
2015
- 2015-01-05 US US14/589,684 patent/US20150119420A1/en not_active Abandoned
- 2015-09-14 US US14/853,826 patent/US20160000774A1/en not_active Abandoned
-
2017
- 2017-04-24 US US15/495,406 patent/US20170224675A1/en not_active Abandoned
- 2017-05-26 JP JP2017104051A patent/JP2017200927A/ja not_active Withdrawn
- 2017-07-27 US US15/662,165 patent/US20170319570A1/en not_active Abandoned
- 2017-11-03 US US15/803,017 patent/US20180050031A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200065A patent/AU2018200065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170319570A1 (en) | 2017-11-09 |
| EP2830623A1 (en) | 2015-02-04 |
| JP2017200927A (ja) | 2017-11-09 |
| SG11201405755QA (en) | 2014-10-30 |
| US20130259856A1 (en) | 2013-10-03 |
| EA201491773A1 (ru) | 2015-02-27 |
| US20150119420A1 (en) | 2015-04-30 |
| JP2015512406A (ja) | 2015-04-27 |
| CA2868259A1 (en) | 2013-10-03 |
| CN105853422A (zh) | 2016-08-17 |
| AR090491A1 (es) | 2014-11-19 |
| IL234687A0 (en) | 2014-11-30 |
| US20160000774A1 (en) | 2016-01-07 |
| US20180050031A1 (en) | 2018-02-22 |
| AU2018200065A1 (en) | 2018-02-01 |
| US20170224675A1 (en) | 2017-08-10 |
| ZA201407722B (en) | 2016-06-29 |
| TW201343164A (zh) | 2013-11-01 |
| KR20150003765A (ko) | 2015-01-09 |
| EP2830623A4 (en) | 2015-09-02 |
| UY34720A (es) | 2013-10-31 |
| HK1205941A1 (en) | 2015-12-31 |
| MX2014011616A (es) | 2014-10-17 |
| AU2013239850A1 (en) | 2014-11-06 |
| WO2013148690A1 (en) | 2013-10-03 |
| CN104470520A (zh) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201407722B (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| ZA201403378B (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| ZA201502503B (en) | Hppd variants and methods of use | |
| IL251397A0 (en) | Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate | |
| ZA201401217B (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| EP2870138A4 (en) | N-SUBSTITUTED BENZAMIDES AND METHOD OF USE THEREOF | |
| SG11201403980VA (en) | Anesthetic compounds and related methods of use | |
| ZA201405858B (en) | Recombinant microorganisms and methods of use thereof | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| IL240014A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| GB201103293D0 (en) | Treatment and prevention of malaria | |
| ZA201504405B (en) | 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof | |
| IL236230A0 (en) | Treatment of multiple sclerosis by a combination of laquinimod and pamperidine | |
| EP2670438A4 (en) | SELECTION AND TREATMENT OF PATIENTS | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| ZA201405829B (en) | Cleaning arrangement and method of use | |
| IL243486A0 (en) | Treatment of multiple sclerosis using a combination of laquinimod and flupirtine | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| IL246078A0 (en) | Treatment of multiple sclerosis by a combination of laquinimod and triflunomide | |
| ME03635B (me) | 6-hlor0-3-(fenil-d5)-inden-1-on i njegova upotreba |